In this short video, Tracy Weslosky of InvestorIntel interviews Chris Thompson of eResearch about eResearch’s Update Report on Xortx Therapeutics pertaining to the Company’s recent $21 million financing and U.S. listing. [more]
New 25-page Update Equity Research Report on XORTX, with a Buy rating and one-year price target of $26.00/share. The Company has two potential late-stage drugs in development focused on kidney diseases with one drug that could be approved within the next 18 months and the other drug that could have an orphan drug indication on the market in 2025. [more]
Patients hospitalized by COVID-19 that end up in intensive care are likely to be diagnosed with acute kidney injury (AKI), face few treatment options and a high mortality rate, but a new potential option is on the way. [more]
XORTX is a biopharmaceutical company focused on developing drugs that could reduce serum acid uric levels. An Initiation Equity Research Report on XORTX was published by eResearch on August 16, 2020. [more]
New 33-page Initiation Equity Research Report on XORTX, with a Speculative Buy rating and one-year price target of $2.30/share. The Company has two potential late stage drugs in development focused on kidney diseases that could initiate pivotal Phase 3 clinical trials in the next 12 months. [more]
Copyright © 2024 | MH Magazine WordPress Theme by MH Themes